妇科肿瘤相关肿瘤标志物的研究现状与进展
Research Status and Progress of Gynecological Tumor Related Tumor Markers
DOI: 10.12677/ACM.2019.91001, PDF,   
作者: 王 敏, 朱国庆, 周义浪, 罗 松, 蒋 梅, 徐 静:贵阳中医学院第二附属医院肿瘤科,贵州 贵阳
关键词: 肿瘤标志物卵巢癌宫颈癌子宫内膜癌Tumor Markers Ovarian Cancer Cervical Cancer Endometrial Cancer
摘要: 妇科三大常见恶性肿瘤包括宫颈癌、子宫内膜癌、卵巢癌,目前临床上对妇科恶性肿瘤的早期筛查手段及方式均欠成熟,导致大多数患者确诊时已处于恶性肿瘤晚期。对妇科肿瘤来说早期诊断至关重要,诊断不及时不仅会延误最佳治疗时期甚至会对患者造成更大的影响。本文对近年来常见妇科肿瘤相关肿瘤标志物的研究现状及进展作一综述。
Abstract: The three common malignant tumors of gynecology include cervical cancer, endometrial cancer, and ovarian cancer. At present, the early screening methods and methods for gynecological ma-lignant tumors are not mature enough, and most patients are already in the late stage of malignant tumors at the time of diagnosis. Early diagnosis of gynecologic tumors is essential, and timely di-agnosis will not only delay the optimal treatment period but will even have a greater impact on patients. This article reviews the research status and progress of common gynecological tu-mor-related tumor markers in recent years.
文章引用:王敏, 朱国庆, 周义浪, 罗松, 蒋梅, 徐静. 妇科肿瘤相关肿瘤标志物的研究现状与进展[J]. 临床医学进展, 2019, 9(1): 1-6. https://doi.org/10.12677/ACM.2019.91001

参考文献

[1] 施小龙. CA125与CA19-9检测在妇科肿瘤诊断中的作用[J]. 慢性病学杂志, 2016, 17(11): 1270-1272.
[2] 郭天利, 焦同立. 血清肿瘤标志物在消化系统恶性肿瘤诊断中的价值[J]. 肿瘤基础与床, 2010, 25(5): 427-428.
[3] 许海, 刘莹. 血清CA19-9、CA125及AFP联合检测在宫颈肿瘤诊断中的应用研究[J]. 热带医学杂志, 2015, 12(6): 766-769, 863.
[4] 中国医师协会检验医师分会妇科肿瘤检验医学专家委员会. 妇科肿瘤标志物应用专家共识[J]. 山东大学学报(医学版), 2018, 56(10): 3-8.
[5] Sopik, V., Iqbal, J., Rosen, B., et al. (2015) Why Have Ovarian Cancer Mortality Rates Declined? Part II. Case-Fatality. Gynecologic Oncology, 138, 750-756.
[6] 马丽娜, 王维琴. 卵巢肿瘤标志物的研究进展[J]. 内蒙古医学杂志, 2016, 48(2): 183-184.
[7] 宋斌斌, 潘柏申. 卵巢癌血清标志物的临床应用[J]. 检验医学, 2015, 30(8): 866-869.
[8] Schummer, M., Ng, W.V., Bumgarner, R.E., et al. (1999) Comparativehy-Bridization of an Array of 21500 Ovarian cDNAs for the Discovery of Genes Overexpressed in Ovarian Carcinomas. Gene, 238, 375-385. [Google Scholar] [CrossRef
[9] 徐仁根, 王君. 7种血清肿瘤标志物对原发性卵巢癌患者的临床诊断研究[J]. 检验医学与临床, 2016, 4(13): 480-481.
[10] 黄璇, 张询. 宫颈癌预后相关分子标志物的研究进展[J]. 肿瘤防治研究, 2016, 43(9): 806-809.
[11] Bin, H., Ruifang, W., Ruizhen, L., et al. (2013) Detention of HPV L1 Capsid Protein and hTERC Gene in Screening of Cervical Cancer. Iranian Journal of Basic Medical Sciences, 16, 797-802.
[12] 齐丽敏, 杨青, 冯晔, 等. TCT联合HPV及jTERC、HER-2和c-myc基因在宫颈高度病变筛查中的临床价值[J]. 现代肿瘤医学, 2015, 23(15): 2180-2183.
[13] Madhumati, G., Kavita, S., Anju, M., et al. (2012) Immunohistochemical Expression of Cell Proliferating Nuclear Antigen (PCNA) and p53 Protein in Cervical Cancer. The Journal of Obstetrics and Gynecology of India, 62, 557-561. [Google Scholar] [CrossRef] [PubMed]
[14] Prunoiu, V.M., Marinca, M.A., Cirimbei, C., et al. (2015) The Configuration of Biomolecular Markers in Cancer of the Uterine Cervix. Personalized Therapy. Monitoring and Prog-nosis. Chirurgia (Bucur), 110, 144-150.
[15] 邬琳, 郭金珠. EGFR和自噬标记蛋白Beclin1在宫颈癌组织中的表达及意义[J]. 实用癌症杂志, 2017, 7(11): 1001-5930.
[16] Gadducci, A., Guerrieri, M.E. and Greco, C. (2013) Tissue, Biomarkers, as Prognostic Variables of Cervical Cancer. Critical Reviews in Oncology/Hematology, 86, 104-129.
[17] 赖小青, 张帆. CA125与HE4联合检测在子宫内膜癌诊断中的价值[J]. 北方药学, 2016, 13(4): 194-195.
[18] 尹绪爱, 马克玉, 肖大树, 等. 经阴道彩色多普勒超声诊断子宫内膜癌的临床分析[J]. 中华妇幼临床医学杂志, 2012, 8(3): 358-360.
[19] 李姣玲, 耿秀平, 伍素卿, 等. 经阴道彩色多普勒超声联合血浆肿瘤标志物检测在子宫内膜癌诊断中的应用[J]. 中华医学超声杂志, 2015, 12(11): 894-900.
[20] 孙苗苗, 南芳芳. 子宫内膜癌相关肿瘤标志物的研究进展[J]. 医学综述, 2016, 22(9): 1701-1703.
[21] 张静, 樊彦卯, 郭战刚, 张志华, 等. CA125、CA19-9、YKL-40、AKT、p-AKT联合检诊断子宫内膜癌的临床价值[J]. 临床合理用药, 2015, 8(3A).
[22] 郝丽娅, 李佩玲. 人附睾蛋白4在子宫内膜癌诊断与治疗中的研究进展[J]. 现代肿瘤医学, 2015, 23(11): 1597-1599.
[23] Moore, R.G., Miller, C.M., Brown, A.K., et al. (2011) Utility of Tumor Marker HE4 to Predict Depth of Myometrial Invasion in Endometrioid Ade-Nocarcinoma of the Uterus. International Journal of Gynecological Cancer, 21, 1185-1190.
[24] Kalogera, E., Scholler, N., Powless, C., et al. (2012) Correlation of Serum HE4 with Tumor Size and Myometrial Invasion in Endometrial Cancer. Gynecologic Oncology, 124, 270-275.